GSK Reports Results of M72/AS01E in P-IIb Study for the Prevention of Pulmonary Tuberculosis Disease

 GSK Reports Results of M72/AS01E in P-IIb Study for the Prevention of Pulmonary Tuberculosis Disease

GSK Reports Results of M72/AS01E in P-IIb Study for the Prevention of Pulmonary Tuberculosis Disease

Shots:

  • The P-IIb study involves assessing of M72/AS01E vs PBO in 3,573 adults in a ratio (1:1) to prevent Mycobacterium tuberculosis infection from developing pulmonary tuberculosis disease in tuberculosis-endemic regions across 11 sites in Kenya, South Africa and Zambia
  • The P-IIb study results demonstrated a reduction in the incidence of pulmonary TB in HIV-negative adults with latent TB infection with an overall efficacy of 50% for three yrs. following vaccination, acceptable safety, and reactogenicity
  • M72/AS01E contains the M72 recombinant fusion protein, derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) combining with its Adjuvant System AS01, providing protection against TB

Click here to­ read full press release/ article | Ref: GSK | Image:  BioTecNika

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post